Moleculin Biotech, Inc. — Director's Dealing 2022

Jul 13, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Moleculin Biotech, Inc. (MBRX)
CIK: 0001659617
Period of Report: 2022-07-11

Reporting Person: KLEMP WALTER V (Director, CEO and President)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-07-11	Common Stock	M	13204	—	Acquired	235650	Direct
2022-07-11	Common Stock	F	3215	$1.68	Disposed	232435	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-07-11	Restricted Stock Units	$	M	13205	Disposed		Common Stock (13204)	Direct

Footnotes

F1: Restricted stock units convert into common stock on a one-for-one basis.

F2: Shares withheld for payment of taxes upon vesting of restricted stock unit awards.

F3: On July 11, 2019, the reporting person was granted 52,818 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date.